402 related articles for article (PubMed ID: 33039585)
21. Effect of Tofacitinib on One-Year Colectomy Risk in Anti-TNF Refractory Ulcerative Colitis: A Prospective Multicenter Italian Study.
Carvalhas Gabrielli AM; Ferretti F; Monico CM; Tombetti E; Maconi G; Romeo S; Piazza O Sed N; Caprioli F; Mazzola AM; Alicante S; Bertè R; Lolli E; Scribano ML; Buscarini E; Ricci C; Carmagnola S; Ardizzone S; Cannatelli R
Dig Dis Sci; 2024 May; 69(5):1785-1792. PubMed ID: 38530500
[TBL] [Abstract][Full Text] [Related]
22. Presence of risk factors associated with colectomy among patients with ulcerative colitis: a
Rubin DT; Salese L; Cohen M; Kotze PG; Woolcott JC; Su C; Mundayat R; Paulissen J; Torres J; Long MD
Therap Adv Gastroenterol; 2023; 16():17562848231189122. PubMed ID: 37560161
[TBL] [Abstract][Full Text] [Related]
23. Corticosteroid-free efficacy and safety outcomes in patients receiving tofacitinib in the OCTAVE Sustain maintenance study.
Vavricka SR; Greuter T; Cohen BL; Reinisch W; Steinwurz F; Fellmann M; Guo X; Lawendy N; Paulissen J; Peyrin-Biroulet L
Therap Adv Gastroenterol; 2022; 15():17562848221090834. PubMed ID: 35574426
[TBL] [Abstract][Full Text] [Related]
24. Exposure-response characterization of tofacitinib efficacy in moderate to severe ulcerative colitis: Results from a dose-ranging phase 2 trial.
Mukherjee A; Hazra A; Smith MK; Martin SW; Mould DR; Su C; Niezychowski W
Br J Clin Pharmacol; 2018 Jun; 84(6):1136-1145. PubMed ID: 29377257
[TBL] [Abstract][Full Text] [Related]
25. Safety of Tofacitinib for Treatment of Ulcerative Colitis, Based on 4.4 Years of Data From Global Clinical Trials.
Sandborn WJ; Panés J; D'Haens GR; Sands BE; Su C; Moscariello M; Jones T; Pedersen R; Friedman GS; Lawendy N; Chan G
Clin Gastroenterol Hepatol; 2019 Jul; 17(8):1541-1550. PubMed ID: 30476584
[TBL] [Abstract][Full Text] [Related]
26. Tofacitinib as Induction and Maintenance Therapy in Japanese Patients with Active Ulcerative Colitis.
Suzuki Y; Watanabe M; Matsui T; Motoya S; Hisamatsu T; Yuasa H; Tabira J; Isogawa N; Tsuchiwata S; Arai S; Hibi T
Inflamm Intest Dis; 2019 Oct; 4(4):131-143. PubMed ID: 31768386
[TBL] [Abstract][Full Text] [Related]
27. Assessment of Safety and Efficacy of Tofacitinib, Stratified by Age, in Patients from the Ulcerative Colitis Clinical Program.
Lichtenstein GR; Bressler B; Francisconi C; Vermeire S; Lawendy N; Salese L; Sawyerr G; Shi H; Su C; Judd DT; Jones T; Loftus EV
Inflamm Bowel Dis; 2023 Jan; 29(1):27-41. PubMed ID: 36342120
[TBL] [Abstract][Full Text] [Related]
28. Tofacitinib induction and maintenance therapy in East Asian patients with active ulcerative colitis: subgroup analyses from three phase 3 multinational studies.
Motoya S; Watanabe M; Kim HJ; Kim YH; Han DS; Yuasa H; Tabira J; Isogawa N; Arai S; Kawaguchi I; Hibi T
Intest Res; 2018 Apr; 16(2):233-245. PubMed ID: 29743836
[TBL] [Abstract][Full Text] [Related]
29. Extraintestinal manifestations at baseline, and the effect of tofacitinib, in patients with moderate to severe ulcerative colitis.
Rubin DT; Reinisch W; Greuter T; Kotze PG; Pinheiro M; Mundayat R; Maller E; Fellmann M; Lawendy N; Modesto I; Vavricka SR; Lichtenstein GR
Therap Adv Gastroenterol; 2021; 14():17562848211005708. PubMed ID: 34035832
[TBL] [Abstract][Full Text] [Related]
30. Clostridium difficile Infection in Patients with Ulcerative Colitis Treated with Tofacitinib in the Ulcerative Colitis Program.
Loftus EV; Baumgart DC; Gecse K; Kinnucan JA; Connelly SB; Salese L; Su C; Kwok KK; Woolcott JC; Armuzzi A
Inflamm Bowel Dis; 2023 May; 29(5):744-751. PubMed ID: 35792493
[TBL] [Abstract][Full Text] [Related]
31. Real-world evidence of tofacitinib effectiveness and safety in patients with refractory ulcerative colitis.
Lair-Mehiri L; Stefanescu C; Vaysse T; Laharie D; Roblin X; Rosa I; Treton X; Abitbol V; Amiot A; Bouguen G; Dib N; Fumery M; Pariente B; Carbonnel F; Peyrin-Biroulet L; Simon M; Viennot S; Bouhnik Y
Dig Liver Dis; 2020 Mar; 52(3):268-273. PubMed ID: 31732444
[TBL] [Abstract][Full Text] [Related]
32. Real-World Experience with Tofacitinib in IBD at a Tertiary Center.
Weisshof R; Aharoni Golan M; Sossenheimer PH; El Jurdi K; Ollech JE; Pekow J; Cohen RD; Sakuraba A; Dalal S; Rubin DT
Dig Dis Sci; 2019 Jul; 64(7):1945-1951. PubMed ID: 30734234
[TBL] [Abstract][Full Text] [Related]
33. Modified Mayo score
Sandborn WJ; Sands BE; Vermeire S; Leung Y; Guo X; Modesto I; Su C; Wang W; Panés J
Therap Adv Gastroenterol; 2022; 15():17562848221136331. PubMed ID: 36506749
[TBL] [Abstract][Full Text] [Related]
34. Characterization of Creatine Kinase Levels in Tofacitinib-Treated Patients with Ulcerative Colitis: Results from Clinical Trials.
Panaccione R; Isaacs JD; Chen LA; Wang W; Marren A; Kwok K; Wang L; Chan G; Su C
Dig Dis Sci; 2021 Aug; 66(8):2732-2743. PubMed ID: 32816215
[TBL] [Abstract][Full Text] [Related]
35. Disease Activity and Health-related Quality of Life Relationships with Work Productivity in Patients with Ulcerative Colitis in OCTAVE Induction 1 and 2 and OCTAVE Sustain.
Targownik L; Dubinsky MC; Steinwurz F; Bushmakin AG; Cappelleri JC; Tai E; Gardiner S; Hur P; Panés J
J Crohns Colitis; 2023 Apr; 17(4):513-523. PubMed ID: 36271912
[TBL] [Abstract][Full Text] [Related]
36. Exposure-Response Characterization of Tofacitinib Efficacy in Moderate to Severe Ulcerative Colitis: Results From Phase II and Phase III Induction and Maintenance Studies.
Mukherjee A; Tsuchiwata S; Nicholas T; Cook JA; Modesto I; Su C; D'Haens GR; Sandborn WJ
Clin Pharmacol Ther; 2022 Jul; 112(1):90-100. PubMed ID: 35380740
[TBL] [Abstract][Full Text] [Related]
37. Outcomes of Tofacitinib Dose Reduction in Patients with Ulcerative Colitis in Stable Remission from the Randomised RIVETING Trial.
Vermeire S; Su C; Lawendy N; Kobayashi T; Sandborn WJ; Rubin DT; Modesto I; Gardiner S; Kulisek N; Zhang H; Wang W; Panés J
J Crohns Colitis; 2021 Jul; 15(7):1130-1141. PubMed ID: 33290538
[TBL] [Abstract][Full Text] [Related]
38. Real-world efficacy and safety of tofacitinib treatment in Asian patients with ulcerative colitis.
Kojima K; Watanabe K; Kawai M; Yagi S; Kaku K; Ikenouchi M; Sato T; Kamikozuru K; Yokoyama Y; Takagawa T; Shimizu M; Shinzaki S
World J Gastroenterol; 2024 Apr; 30(13):1871-1886. PubMed ID: 38659488
[TBL] [Abstract][Full Text] [Related]
39. Tofacitinib for the Treatment of Ulcerative Colitis: Analysis of Infection Rates from the Ulcerative Colitis Clinical Programme.
Winthrop KL; Loftus EV; Baumgart DC; Reinisch W; Nduaka CI; Lawendy N; Chan G; Mundayat R; Friedman GS; Salese L; Thorpe AJ; Su C
J Crohns Colitis; 2021 Jun; 15(6):914-929. PubMed ID: 33245746
[TBL] [Abstract][Full Text] [Related]
40. Randomized trial of tofacitinib in active ulcerative colitis: analysis of efficacy based on patient-reported outcomes.
Panés J; Su C; Bushmakin AG; Cappelleri JC; Mamolo C; Healey P
BMC Gastroenterol; 2015 Feb; 15():14. PubMed ID: 25651782
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]